McGill Raquel B, Steyn Frederik J, Ngo Shyuan T, Thorpe Kathryn A, Heggie Susan, Ruitenberg Marc J, Henderson Robert D, McCombe Pamela A, Woodruff Trent M
School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia.
Wesley Medical Research, The Wesley Hospital, Brisbane, Queensland 4066, Australia.
Brain Commun. 2020 Feb 14;2(1):fcaa013. doi: 10.1093/braincomms/fcaa013. eCollection 2020.
Immunity has emerged as a key player in neurodegenerative diseases such as amyotrophic lateral sclerosis, with recent studies documenting aberrant immune changes in patients and animal models. A challenging aspect of amyotrophic lateral sclerosis research is the heterogeneous nature of the disease. In this study, we investigate the associations between peripheral blood myeloid cell populations and clinical features characteristic of amyotrophic lateral sclerosis. Peripheral blood leukocytes from 23 healthy controls and 48 patients with amyotrophic lateral sclerosis were analysed to measure myeloid cell alterations. The proportion of monocytes (classical, intermediates and non-classical subpopulations) and neutrophils, as well as the expression of select surface markers, were quantitated using flow cytometry. Given the heterogeneous nature of amyotrophic lateral sclerosis, multivariable linear analyses were performed to investigate associations between patients' myeloid profile and clinical features, such as the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, bulbar subscore of the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, change in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale over disease duration and respiratory function. We demonstrate a shift in monocyte subpopulations in patients with amyotrophic lateral sclerosis, with the ratio of classical to non-classical monocytes increased compared with healthy controls. In line with this, patients with greater disease severity, as determined by a lower Revised Amyotrophic Lateral Sclerosis Functional Rating Scale score, had reduced non-classical monocytes. Interestingly, patients with greater bulbar involvement had a reduction in the proportions of classical, intermediate and non-classical monocyte populations. We also revealed several notable associations between myeloid marker expression and clinical features in amyotrophic lateral sclerosis. CD16 expression on neutrophils was increased in patients with greater disease severity and a faster rate of disease progression, whereas HLA-DR expression on all monocyte populations was elevated in patients with greater respiratory impairment. This study demonstrates that patients with amyotrophic lateral sclerosis with distinct clinical features have differential myeloid cell signatures. Identified cell populations and markers may be candidates for targeted mechanistic studies and immunomodulation therapies in amyotrophic lateral sclerosis.
免疫已成为肌萎缩侧索硬化等神经退行性疾病的关键因素,最近的研究记录了患者和动物模型中异常的免疫变化。肌萎缩侧索硬化研究的一个具有挑战性的方面是该疾病的异质性。在本研究中,我们调查外周血髓样细胞群与肌萎缩侧索硬化临床特征之间的关联。分析了23名健康对照者和48名肌萎缩侧索硬化患者的外周血白细胞,以测量髓样细胞的改变。使用流式细胞术对单核细胞(经典、中间和非经典亚群)和中性粒细胞的比例以及选定表面标志物的表达进行定量。鉴于肌萎缩侧索硬化的异质性,进行了多变量线性分析,以研究患者的髓样特征与临床特征之间的关联,如修订的肌萎缩侧索硬化功能评定量表、修订的肌萎缩侧索硬化功能评定量表的延髓亚评分、修订的肌萎缩侧索硬化功能评定量表在疾病持续时间内的变化以及呼吸功能。我们证明了肌萎缩侧索硬化患者单核细胞亚群的转变,与健康对照相比,经典单核细胞与非经典单核细胞的比例增加。与此一致的是,根据较低的修订肌萎缩侧索硬化功能评定量表评分确定,疾病严重程度较高的患者非经典单核细胞减少。有趣的是,延髓受累程度较高的患者经典、中间和非经典单核细胞群体的比例降低。我们还揭示了肌萎缩侧索硬化中髓样标志物表达与临床特征之间的几个显著关联。疾病严重程度较高且疾病进展速度较快的患者中性粒细胞上的CD16表达增加,而呼吸功能损害较大的患者所有单核细胞群体上的HLA-DR表达升高。这项研究表明,具有不同临床特征的肌萎缩侧索硬化患者具有不同的髓样细胞特征。确定的细胞群和标志物可能是肌萎缩侧索硬化靶向机制研究和免疫调节治疗的候选对象。